...
首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >The Efficacy and Safety of Traditional Chinese Medicine (Jiang Zhi Granule) for Nonalcoholic Fatty Liver: A Multicenter, Randomized, Placebo-Controlled Study
【24h】

The Efficacy and Safety of Traditional Chinese Medicine (Jiang Zhi Granule) for Nonalcoholic Fatty Liver: A Multicenter, Randomized, Placebo-Controlled Study

机译:中药(姜志颗粒)对非酒精性脂肪肝的疗效和安全性:多中心,随机,安慰剂对照研究

获取原文

摘要

Objective. To evaluate the efficacy and safety of Jiang Zhi Granule (JZG), a Chinese herbal formula, in patients with nonalcoholic fatty liver (NAFL).Methods. A multicenter, randomized, double-blind, placebo-controlled, parallel clinical trial was conducted for 24 weeks in 224 patients with NAFL at 6 university-affiliated hospitals. Patients were randomized 1 : 1 to receive JZG and placebo, respectively. Primary outcome was the change of liver to spleen ratio (L/S ratio) over computed tomography (CT). Secondary outcomes included body mass index (BMI), serum triglyceride (TG), and total cholesterol (TC) levels.Results. Of all the 224 eligible patients, 221 patients were analyzed in the full analysis set (FAS), 205 in the per protocol set (PPS), and 3 patients were withdrawn prematurely. For FAS, JZG significantly increased L/S ratio from 0.74 ± 0.21 to 0.99 ± 0.24 compared to that from 0.79 ± 0.18 to 0.85 ± 0.27 in placebo group (P=0.0011). For PPS, it showed an increase of 0.26 ± 0.23 of L/S ratio in the patients on JZG versus 0.07 ± 0.22 in those on placebo (P=0.0003). Superiority of JZG over placebo was also observed with greater reduction in BMI (P<0.05) in both FAS and PPS. No observable difference in decrease of serum TC and TG was recorded (P>0.05). There were no serious adverse events (AEs) in the study process and safety indices were normal in both groups.Conclusions. The Chinese herbal formula JZG was found to be superior to placebo in increasing L/S ratio and reducing BMI in NAFL patients. It was also well tolerated in patients and might be a safe and effective medicine for NAFL.
机译:客观的。评估江智颗粒(JZG),中草原,非酒精性脂肪肝(NAFL)的疗效和安全性。方法。在624名附属医院的224名NAFL患者中,在224名患者中进行了多中心,随机,双盲,安慰剂控制的并行临床试验。患者分别随机1:1分别接受JZG和安慰剂。主要结果是在计算机断层扫描(CT)上的肝脏与脾脏比率(L / S比率)的变化。二次结果包括体重指数(BMI),血清甘油三酯(TG)和总胆固醇(TC)水平。结果。在所有224名符合条件的患者中,221名患者在全分析组(FAS)中分析了每种协议组(PPS)的205例,3例患者过早撤回。对于Fas,与安慰剂组中的0.79±0.18至0.85±0.27相比,JZG显着增加L / S比率为0.74±0.21至0.99±0.24(P = 0.0011)。对于PPS而言,在安慰剂上的那些中,患者在JZG的患者中增加了0.26±0.23的L / S比率(P = 0.0003)。在FAS和PPS中,也观察到JZG过度安慰剂的优越性也观察到BMI(P <0.05)减少。记录血清Tc和Tg降低的可观察差异(p> 0.05)。在研究过程中没有严重的不良事件(AES),并且两组中的安全指数都是正常的.Conclusions。发现中草原jzg在增加L / S比率和降低NAFL患者中的BMI时,中草原jzg优于安慰剂。它在患者中也是良好的耐受性,并且可能是NAFL的安全有效的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号